---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-007972"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T06:13:24.809843+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology: $75M cash, 50% ORR in ONSEMBLE bev naïve, first patient dosed in CRDF-004 trial

## Summary
- Cash and equivalents of $75M as of Dec 31, 2023; projected runway into Q3 2025.
- ONSEMBLE: 50% ORR (2/4) in bev naïve patients on onvansertib+SoC vs 0% in control; no responses in bev exposed.
- First patient dosed in Phase 2 first-line CRDF-004 trial for RAS-mutated mCRC; topline data expected mid-2024.
- Pfizer Ignite handling clinical execution; FDA accepted ORR as endpoint for potential accelerated approval.
- FY2023 operating expenses $45.9M, net cash used $30.9M; decrease from $33.8M in FY2022.

## SEC filing metadata
- accession: 0001628280-24-007972
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828024007972/0001628280-24-007972-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828024007972/crdf-20240229.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-007972
- JSON: https://secwatch.observer/filing/0001628280-24-007972.json
- Plain text: https://secwatch.observer/filing/0001628280-24-007972.txt

## Key facts
- Earnings Releases
  Cardiff Oncology, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On February 29, 2024, Cardiff Oncology, Inc. (the “Company”) issued a press release announcing company highlights and financial results for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1213037/000162828024007972/0001628280-24-007972-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.